Navigation Links
New Pharmaxis Board Appointment
Date:4/6/2009

SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors.

Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. HSMR Advisors has held a position on the Pharmaxis share register since 2005.

During his career Mr van den Broek has worked on both the buy and sell side of the funds management industry holding senior positions at Cooper Hill Partners, Hambrecht & Quist (H&Q), Merrill Lynch and Oppenheimer & Co.

"Richard has been an engaged investor for a number of years and has great insight into the life science industry and the U.S. capital markets," said Pharmaxis Chief Executive Officer, Dr Alan Robertson. "Our shareholders will benefit from his skills and experience."

In accepting the board position Mr van den Broek said: "Pharmaxis holds enormous promise and I look forward to being part of an exciting company at a key point in its development as a global provider of innovative medicines.

I am very much looking forward to working with the Pharmaxis Board."

Mr van den Broek is a Chartered Financial Analyst, and is a graduate of Harvard University.

    For information on all Pharmaxis Board members, go to:
   http://www.pharmaxis.com.au/about-us/our-people/our-people_home.cfm

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson -- Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:
     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

    United States:
     Brandon Lewis, Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Investor Conference Call
2. Pharmaxis Appoints French Distributor for Aridol(TM)
3. Pharmaxis Builds Senior Management Team
4. Pharmaxis Investor Conference Call
5. Pharmaxis Aridol Approved for Sale in Switzerland
6. Pharmaxis Investor Conference Call
7. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
8. New Pharmaxis Board Appointment
9. Pharmaxis Aridol Authorised for Sale in Germany
10. Pharmaxis First Steps into China
11. Pharmaxis to Apply to Market Bronchitol in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
(Date:10/7/2017)... WA (PRWEB) , ... October ... ... industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution ... ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome ...
Breaking Biology Technology:
(Date:8/23/2017)... 2017  The general public,s help is being enlisted in what,s thought ... in and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the ... with the gut. The project's goal is to help advance scientific knowledge ... ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):